Previous Close | 3.3200 |
Open | 3.2800 |
Bid | 2.9500 x 1200 |
Ask | 3.3000 x 1000 |
Day's Range | 3.1500 - 3.4159 |
52 Week Range | 1.9600 - 7.9000 |
Volume | |
Avg. Volume | 161,520 |
Market Cap | 300.002M |
Beta (5Y Monthly) | 1.39 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.8420 |
Earnings Date | Aug 04, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.06 |
Subscribe to Yahoo Finance Plus to view Fair Value for AUTL
- Conference call to be held on August 4, 2022 at 8:30 am ET/1:30 pm BST -LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the second quarter ended June 30, 2022. “Autolus has had a successful second quarter, with progress made across all fronts. We were awarded Regenerative Medicine Advanced Therapy (RMAT)
In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call, and replaces the earlier version LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2022 financial results and operational highlights before open of U.S. mar
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2022 financial results and operational highlights before open of U.S. markets on Thursday, August 4, 2022. Management will host a conference call and webcast at 8:30 am ET/1:30 pm BST to discuss the company’s financial results and provide a general business upda